Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer s drug flops
Get the Full StoryShares in the pharmaceutical company fell a staggering 85 on Monday after it reported disappointing Phase 3 results, but its problems started way before that.In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration FDA that cast doubt on the positive trial results of its novel Alzheimer s drug, simufilam.
Share: